Healing effect of a fibrin-based scaffold loaded with platelet lysate in full-thickness skin wounds

Abstract

Chronic skin lesions are difficult to heal due to reduced levels and activity of endogenous growth factors. The platelet lysate, obtained by repeated freeze–thawing of platelet-enriched blood samples, is an easily attainable source of a wide range of growth factors and bioactive mediators involved in tissue repair. In this study, a bio-synthetic scaffold composed of poly(ether)urethane–polydimethylsiloxane material and fibrin was developed for platelet lysate delivery to chronic skin wounds. The kinetics release and the bioactivity of growth factors released from platelet lysate–loaded poly(ether)urethane–polydimethylsiloxane–fibrin scaffold were investigated, respectively, by enzyme-linked immunosorbent assay and a cell proliferation test using human fibroblasts. The in vitro experiments demonstrated that the platelet lysate–loaded poly(ether)urethane–polydimethylsiloxane–fibrin scaffold provides a sustained release of platelet derived growth factors. The cell growth in the presence of scaffold was comparable to those observed for the platelet lysate added to culture medium in free form, showing that the scaffold preparation process did not affect biological activity of growth factors. The effect of platelet lysate–loaded poly(ether)urethane–polydimethylsiloxane–fibrin scaffold on wound healing in genetically diabetic mouse (db/db) was also investigated. The application of the scaffold on full-thickness skin wounds significantly accelerated wound closure at day 15 post-surgery compared with control poly(ether)urethane–polydimethylsiloxane–fibrin scaffold (without platelet lysate) or a commercially available polyurethane film dressing. Histological analysis demonstrated an increased re-epithelialization, granulation tissue formation, and collagen deposition. The ability of the platelet lysate–loaded poly(ether)urethane–polydimethylsiloxane–fibrin scaffold to promote wound healing in vivo through simultaneous delivery of multiple active substances suggests its potential use for the treatment of diabetic foot ulcers.

Keywords

Platelet lysate poly(ether)urethane–polydimethylsiloxane scaffold fibrin diabetic mice wound healing

Get full access to this article

View all access options for this article.

References

Goldman

. Growth factors and chronic wound healing: past, present, and future. Adv Skin Wound Care 2004; 17: 24–35.

Blakytny

Jude

. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 2006; 23: 594–608.

Wokalek

Ruh

. Time course of wound healing. J Biomater Appl 1991; 5: 337–362.

Lerman

Galiano

Armour

. Cellular dysfunction in the diabetic fibroblast: impairment in migration, vascular endothelial growth factor production, and response to hypoxia. Am J Pathol 2003; 162: 303–312.

Bitar

Labbad

. Transforming growth factor-beta and insulin-like growth factor-I in relation to diabetes-induced impairment of wound healing. J Surg Res 1996; 15: 113–119.

Tan

Chen

Yan

. Promotion of diabetic wound healing by collagen scaffold with collagen-binding vascular endothelial growth factor in a diabetic rat model. J Tissue Eng Regen Med 2014; 8: 195–201.

Kanda

Morimoto

Ayvazyan

. Evaluation of a novel collagen-gelatin scaffold for achieving the sustained release of basic fibroblast growth factor in a diabetic mouse model. J Tissue Eng Regen Med 2014; 8: 29–40.

Davidson

Guelcher

. The effect of the local delivery of platelet-derived growth factor from reactive two-component polyurethane scaffolds on the healing in rat skin excisional wounds. Biomaterials 2009; 30: 3486–3494.

Hanft

Pollak

Barbul

. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers. J Wound Care 2008; 17: 30–32, 34–37.

10.

Uchi

Igarashi

Urabe

. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol 2009; 19: 461–468.

11.

Richard

Parer-Richard

Daures

. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. Diabetes Care 1995; 18: 64–69.

12.

Trengove

Stacey

MacAuley

. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7: 442–452.

13.

Ackermann

Wolloscheck

Wellmann

. Priming with a combination of proangiogenic growth factors enhances wound healing in streptozotocin-induced diabetes in mice. Eur Surg Res 2011; 47: 81–89.

14.

Brown

Breeden

Greenhalgh

. PDGF and TGF-alpha act synergistically to improve wound healing in the genetically diabetic mouse. J Surg Res 1994; 56: 562–570.

15.

Briganti

Spiller

Mirtelli

. A composite fibrin-based scaffold for controlled delivery of bioactive pro-angiogenetic growth factors. J Control Release 2010; 142: 14–21.

16.

Losi

Briganti

Magera

. Tissue response to poly(ether)urethane-polydimethylsiloxane-fibrin composite scaffolds for controlled delivery of pro-angiogenic growth factors. Biomaterials 2010; 31: 5336–5344.

17.

Losi

Briganti

Errico

. Fibrin-based scaffold incorporating VEGF- and bFGF-loaded nanoparticles stimulates wound healing in diabetic mice. Acta Biomater 2013; 9: 7814–7821.

18.

Doucet

Ernou

Zhang

. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005; 205: 228–236.

19.

Margolis

Kantor

Santanna

. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001; 24: 483–488.

20.

Ito

Morimoto

Pham

. Efficacy of the controlled release of concentrated platelet lysate from a collagen/gelatin scaffold for dermis-like tissue regeneration. Tissue Eng Part A 2013; 19: 1398–1405.

21.

Barsotti

Losi

Briganti

. Effect of platelet lysate on human cells involved in different phases of wound healing. PLoS ONE 2013; 27: e84753.

22.

Briganti

Losi

Raffi

. Silicone based polyurethane materials: a promising biocompatible elastomeric formulation for cardiovascular applications. J Mater Sci Mater Med 2006; 17: 259–266.

23.

Pandit

Feldman

Caulfield

. In vivo wound healing response to a modified degradable fibrin scaffold. J Biomater Appl 1998; 12: 222–236.

24.

Pandit

Wilson

Feldman

. Fibrin scaffold as an effective vehicle for the delivery of acidic fibroblast growth factor (FGF-1). J Biomater Appl 2000; 14: 229–242.

25.

Sahni

Baker

Sporn

. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost 2000; 83: 736–741.

26.

Lundquist

Dziegiel

Agren

. Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin. Wound Repair Regen 2008; 16: 356–363.

27.

Anitua

Aguirre

Algorta

. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater 2008; 84: 415–421.

28.

Ranzato

Martinotti

Volante

. Platelet lysate modulates MMP-2 and MMP-9 expression, matrix deposition and cell-to-matrix adhesion in keratinocytes and fibroblasts. Exp Dermatol 2011; 20: 308–313.

29.

El Backly

Ulivi

Tonachini

. Platelet lysate induces in vitro wound healing of human keratinocytes associated with a strong proinflammatory response. Tissue Eng Part A 2011; 17: 1787–1800.

30.

Savarino

Cenni

Tarabusi

. Evaluation of bone healing enhancement by lyophilized bone grafts supplemented with platelet gel: a standardized methodology in patients with tibial osteotomy for genu varus. J Biomed Mater Res B Appl Biomater 2006; 76: 364–372.

31.

Suzuki

Morimoto

Ikada

. Gelatin gel as a carrier of platelet-derived growth factors. J Biomater Appl 2013; 28: 595–606.

32.

Obara

Ishihara

Ishizuka

. Photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 stimulates wound healing in healing-impaired db/db mice. Biomaterials 2003; 24: 3437–3444.

33.

Kondo

Kuroyanagi

. Development of a wound dressing composed of hyaluronic acid and collagen sponge with epidermal growth factor. J Biomater Sci Polym Ed 2012; 23: 629–643.